565 related articles for article (PubMed ID: 30721724)
1. Development of an amorphous nanosuspension by sonoprecipitation-formulation and process optimization using design of experiment methodology.
Gajera BY; Shah DA; Dave RH
Int J Pharm; 2019 Mar; 559():348-359. PubMed ID: 30721724
[TBL] [Abstract][Full Text] [Related]
2. A quality-by-design study to develop Nifedipine nanosuspension: examining the relative impact of formulation variables, wet media milling process parameters and excipient variability on drug product quality attributes.
Patel PJ; Gajera BY; Dave RH
Drug Dev Ind Pharm; 2018 Dec; 44(12):1942-1952. PubMed ID: 30027778
[TBL] [Abstract][Full Text] [Related]
3. Enhanced Solubility and Dissolution Rate of Lacidipine Nanosuspension: Formulation Via Antisolvent Sonoprecipitation Technique and Optimization Using Box-Behnken Design.
Kassem MAA; ElMeshad AN; Fares AR
AAPS PharmSciTech; 2017 May; 18(4):983-996. PubMed ID: 27506564
[TBL] [Abstract][Full Text] [Related]
4. Investigating a Novel Hot Melt Extrusion-Based Drying Technique to Solidify an Amorphous Nanosuspension Using Design of Experiment Methodology.
Gajera BY; Shah DA; Dave RH
AAPS PharmSciTech; 2018 Nov; 19(8):3778-3790. PubMed ID: 30280356
[TBL] [Abstract][Full Text] [Related]
5. Cefdinir nanosuspension for improved oral bioavailability by media milling technique: formulation, characterization and in vitro-in vivo evaluations.
Sawant KK; Patel MH; Patel K
Drug Dev Ind Pharm; 2016; 42(5):758-68. PubMed ID: 26548349
[TBL] [Abstract][Full Text] [Related]
6. Risk assessment and QbD based optimization of an Eprosartan mesylate nanosuspension: In-vitro characterization, PAMPA and in-vivo assessment.
Shekhawat P; Pokharkar V
Int J Pharm; 2019 Aug; 567():118415. PubMed ID: 31175989
[TBL] [Abstract][Full Text] [Related]
7. Fabrication of Ibrutinib Nanosuspension by Quality by Design Approach: Intended for Enhanced Oral Bioavailability and Diminished Fast Fed Variability.
Rangaraj N; Pailla SR; Chowta P; Sampathi S
AAPS PharmSciTech; 2019 Oct; 20(8):326. PubMed ID: 31659558
[TBL] [Abstract][Full Text] [Related]
8. Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.
Karakucuk A; Celebi N; Teksin ZS
Eur J Pharm Sci; 2016 Dec; 95():111-121. PubMed ID: 27181836
[TBL] [Abstract][Full Text] [Related]
9. Development of olmesartan medoxomil optimized nanosuspension using the Box-Behnken design to improve oral bioavailability.
Nagaraj K; Narendar D; Kishan V
Drug Dev Ind Pharm; 2017 Jul; 43(7):1186-1196. PubMed ID: 28271908
[TBL] [Abstract][Full Text] [Related]
10. Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.
Jain S; Reddy VA; Arora S; Patel K
Drug Deliv Transl Res; 2016 Oct; 6(5):498-510. PubMed ID: 27129488
[TBL] [Abstract][Full Text] [Related]
11. Preparation and Characterization of Stable Nanosuspension for Dissolution Rate Enhancement of Furosemide: A Quality by Design (QbD) Approach.
Marzan AL; Tabassum R; Jahan B; Asif MH; Reza HM; Kazi M; Alshehri SM; de Matas M; Shariare MH
Curr Drug Deliv; 2018; 15(5):672-685. PubMed ID: 29359667
[TBL] [Abstract][Full Text] [Related]
12. Investigation of nanosized crystalline form to improve the oral bioavailability of poorly water soluble cilostazol.
Miao X; Sun C; Jiang T; Zheng L; Wang T; Wang S
J Pharm Pharm Sci; 2011; 14(2):196-214. PubMed ID: 21733409
[TBL] [Abstract][Full Text] [Related]
13. Application of Central Composite Design in Optimization of Valsartan Nanosuspension to Enhance its Solubility and Stability.
Vuppalapati L; Cherukuri S; Neeli V; Yeragamreddy PR; Kesavan BR
Curr Drug Deliv; 2016; 13(1):143-57. PubMed ID: 26205900
[TBL] [Abstract][Full Text] [Related]
14. Formulation, optimization and in vitro-in vivo evaluation of febuxostat nanosuspension.
Ahuja BK; Jena SK; Paidi SK; Bagri S; Suresh S
Int J Pharm; 2015 Jan; 478(2):540-52. PubMed ID: 25490182
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of solubility, antioxidant ability and bioavailability of taxifolin nanoparticles by liquid antisolvent precipitation technique.
Zu Y; Wu W; Zhao X; Li Y; Wang W; Zhong C; Zhang Y; Zhao X
Int J Pharm; 2014 Aug; 471(1-2):366-76. PubMed ID: 24882039
[TBL] [Abstract][Full Text] [Related]
16. Design of selegiline-loaded bio-nanosuspension for the management of depression using novel bio-retardant from
Tyagi Y; Madhav NVS
Drug Dev Ind Pharm; 2019 Aug; 45(8):1351-1360. PubMed ID: 31084445
[No Abstract] [Full Text] [Related]
17. Exploration of alginates as potential stabilizers of nanosuspension.
Guan J; Zhang Y; Liu Q; Zhang X; Chokshi R; Mao S
AAPS PharmSciTech; 2017 Nov; 18(8):3172-3181. PubMed ID: 28536795
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of the apparent solubility and bioavailability of Tadalafil nanoparticles via antisolvent precipitation.
Rao Q; Qiu Z; Huang D; Lu T; Zhang ZJ; Luo D; Pan P; Zhang L; Liu Y; Guan S; Li Q
Eur J Pharm Sci; 2019 Feb; 128():222-231. PubMed ID: 30553058
[TBL] [Abstract][Full Text] [Related]
19. In vitro dissolution enhancement of micronized l-nimodipine by antisolvent re-crystallization from its crystal form H.
Zu Y; Li N; Zhao X; Li Y; Ge Y; Wang W; Wang K; Liu Y
Int J Pharm; 2014 Apr; 464(1-2):1-9. PubMed ID: 24456674
[TBL] [Abstract][Full Text] [Related]
20. [Preparation and characterization of icariin nanosuspension and lyophilized powder].
Hui-Rong XI; Hui-Ping MA; Ke-Ming C; Xiao-Shuan L
Zhongguo Zhong Yao Za Zhi; 2020 Oct; 45(20):4902-4908. PubMed ID: 33350263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
